Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Weight Reduction

irinotecan has been researched along with Weight Reduction in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.00)18.2507
2000's8 (40.00)29.6817
2010's9 (45.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Chen, D; Gao, F; Kan, S; Lu, C; Qian, Z; Yin, Y; Zhu, H1
Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF1
Aziz, M; Kao, CT; Kasi, A1
Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA1
Aragão, KS; Costa, ML; de Almeida, PR; de Castro Brito, GA; de Mesquita Neto, JW; de Sá Grassi, L; de Souza, MH; Leite, LL; Lima-Júnior, RC; Marques-Neto, RD; Medeiros, RP; Nunes, LG; Ribeiro, RA1
Cheng, YC; Chu, E; Guan, F; Hu, R; Jiang, Z; Lam, W; Liu, SH1
de Bruijn, P; de Bruin, RW; Ghobadi Moghaddam-Helmantel, IM; Huisman, SA; IJzermans, JN; Mathijssen, RH; Wiemer, EA1
Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP1
Arantes, RM; Bastos, RW; Cardoso, VN; Cartelle, CT; França, CS; Generoso, SV; Martins, FS; Moreira, LM; Neves, MJ; Nicoli, JR; Pedroso, SH; Vieira, AT1
Banzi, C; Biasco, G; Bonetti, F; Boni, C; Brandes, A; Calandri, C; Carandina, I; Cataldo, S; DI Fabio, F; Lelli, G; Marzola, M; Nanni, O; Negri, F; Panetta, A; Pantaleo, MA; Ravaioli, E; Turci, D; Urbini, B1
Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ1
Cicin, I; Sezer, A; Usta, U1
Bussom, S; Cheng, YC; Guan, F; Gullen, EA; Jiang, Z; Lam, W; Liu, SH; Zhang, W1
Iwata, T; Komatsu, M; Kurita, N; Nakao, T; Shimada, M; Utusnomiya, T; Yoshikawa, K1
Davis, TW; Durham, WF; Horton, J; Levine, BD; Masferrer, JL; Salazar, VS; Trifan, OC; Zweifel, BS1
Filipski, E; Lemaigre, G; Lévi, F; Liu, XH; Mahjoubi, M; Méry-Mignard, D1
Fushiki, H1
Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S1
Bian, JS; Chan, E; Duan, W; Hu, ZP; Huang, M; Li, X; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ1
Higuchi, S; Ishizaki, T; Makinosumi, T; Nakano, S; Ogawa, N; Ohdo, S; Yukawa, E1

Reviews

1 review(s) available for irinotecan and Weight Reduction

ArticleYear
[Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytokines; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Hematopoiesis; Humans; Irinotecan; Leukopenia; Lymphocyte Activation; Mice; Nausea; Peripheral Nervous System Diseases; Phytotherapy; Thrombocytopenia; Vomiting; Weight Loss

2004

Trials

3 trial(s) available for irinotecan and Weight Reduction

ArticleYear
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
    International journal of cancer, 2022, 01-01, Volume: 150, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Weight Loss

2022
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss

2015
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Weight Loss

2005

Other Studies

16 other study(ies) available for irinotecan and Weight Reduction

ArticleYear
Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Animals; Bifidobacterium longum; Cell Line; Chemical and Drug Induced Liver Injury; Cytokines; Diarrhea; Disease Models, Animal; Feces; Gastrointestinal Microbiome; Inflammation Mediators; Intestines; Irinotecan; Liver; Mice, Inbred BALB C; Oxidative Stress; Probiotics; Rats; Selenium; Tight Junction Proteins; Weight Loss

2021
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
    BMJ case reports, 2018, Sep-01, Volume: 2018

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Tomography, X-Ray Computed; Weight Loss

2018
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
    International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss

2014
Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Alanine Transaminase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fatty Liver; Humans; Interleukin-1beta; Irinotecan; Liver; Male; Mice; Peroxidase; Time Factors; Tumor Necrosis Factor-alpha; Weight Loss

2014
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
    BMC complementary and alternative medicine, 2014, Dec-15, Volume: 14

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Colonic Neoplasms; Drugs, Chinese Herbal; Female; Granulocyte Colony-Stimulating Factor; Humans; Intestinal Mucosa; Intestines; Irinotecan; Mice; Neutrophil Infiltration; Phytotherapy; Receptors, G-Protein-Coupled; RNA, Messenger; Tumor Necrosis Factor-alpha; Weight Loss

2014
Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
    British journal of pharmacology, 2016, Volume: 173, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Fasting; Glucuronides; Irinotecan; Leukopenia; Liver; Male; Mice, Inbred BALB C; RNA, Messenger; Treatment Outcome; Tumor Burden; Weight Loss

2016
Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis.
    Beneficial microbes, 2016, Volume: 7, Issue:4

    Topics: Animals; Camptothecin; Disease Models, Animal; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Irinotecan; Jejunum; Lipid Peroxidation; Male; Mice; Mucositis; Oxidative Stress; Probiotics; Saccharomyces cerevisiae; Weight Loss

2016
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Skin; Skin Diseases; Weight Loss

2008
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays

2008
The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Histocytochemistry; Irinotecan; Leukocytes; Mucositis; Rats; Saccharomyces; Weight Loss

2009
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.
    Science translational medicine, 2010, Aug-18, Volume: 2, Issue:45

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Biomarkers, Tumor; Bromodeoxyuridine; Camptothecin; Cell Proliferation; DNA Damage; Drugs, Chinese Herbal; Gastrointestinal Tract; Glucuronidase; Humans; Inflammation; Irinotecan; Medicine, Chinese Traditional; Mice; Proliferating Cell Nuclear Antigen; Recovery of Function; Signal Transduction; Stem Cells; Transplantation, Homologous; Weight Loss; Wnt Proteins; Wnt3 Protein; Wnt3A Protein

2010
Irinotecan injures tight junction and causes bacterial translocation in rat.
    The Journal of surgical research, 2012, Volume: 173, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Translocation; Camptothecin; Claudin-1; Diarrhea; Intestinal Mucosa; Irinotecan; Male; Membrane Proteins; Occludin; Permeability; Rats; Rats, Wistar; RNA, Messenger; Tight Junctions; Weight Loss

2012
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
    Cancer research, 2002, Oct-15, Volume: 62, Issue:20

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Dinoprostone; Drug Administration Schedule; Drug Synergism; HT29 Cells; Humans; Irinotecan; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Weight Loss; Xenograft Model Antitumor Assays

2002
Circadian rhythm of irinotecan tolerability in mice.
    Chronobiology international, 2004, Volume: 21, Issue:4-5

    Topics: Agranulocytosis; Animals; Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Chronotherapy; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Intestines; Irinotecan; Leukopenia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Photoperiod; Topoisomerase I Inhibitors; Weight Loss

2004
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Blood Proteins; Bone Marrow; Caco-2 Cells; Camptothecin; Diarrhea; Hepatocytes; Humans; Intestines; Irinotecan; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thalidomide; Tumor Necrosis Factor-alpha; Weight Loss

2006
Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 283, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Cell Cycle; Circadian Rhythm; Irinotecan; Leukocyte Count; Male; Mice; Mice, Inbred ICR; Time Factors; Weight Loss

1997